Have any questions? 706-721-6582 or cts@augusta.edu
- C-145-04: A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma
Clinical Trial
C-145-04: A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma
Iovance Biotherapeutic, Inc. (the Sponsor) is carrying out this study to find out if an Investigational Medicinal Product (IMP), called LN-145 (referred to as investigational product) is safe and beneficial in the treatment of patients with recurrent, metastatic or persistent cervical cancer when previous treatment has not worked.
Eligibility Criteria
- Subjects must be at least 18 years of ager or older. Subjects must have recurrent, metastatic, or persistent squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix, which is not amenable to curative treatment with surgery and/or radiation therapy. Subjects who have received prior cell transfer therapy exceopt for prior LN-145 therapy are not eligible for this study.
RESEARCH. INNOVATION. DISCOVERY.